The Next Semiconductor - Lawfare

This article explores how data fragmentation in biomanufacturing is undermining U.S. competitiveness in the biotechnology and pharmaceutical sectors. Despite the strategic value of the massive amounts... Read original →

Data fragmentation in biomanufacturing is becoming a systemic vulnerability for U.S. biotech competitiveness. Technically, the misalignment between SaaS architectures and FDA’s CSA guidance disrupts end-to-end data flows—from sensors to ERP systems like SAP—slowing process optimization and scale-up. Regulatory ambiguity inflates validation costs and weakens supply chain resilience, especially in multi-cloud environments. China, by contrast, leverages centralized digital infrastructure and unified data standards to build closed-loop bio-manufacturing ecosystems, gaining asymmetric leverage. Over the next 12–24 months, without enforceable cross-company data interoperability frameworks, the U.S. will erode its lead in advanced therapies and biodefense. Chinese firms could seize control of global bio-manufacturing API standards, mirroring the strategic capture seen in semiconductor EDA markets.